## World Health Organization (WHO)-prequalified typhoid conjugate vaccines

**Programmatic characteristics**

<table>
<thead>
<tr>
<th>MANUFACTURER</th>
<th>Typbar TCV®</th>
<th>TYPHIBEV®</th>
</tr>
</thead>
<tbody>
<tr>
<td>BHARAT BIOTEC, INDIA</td>
<td>Bharat Biotech, India</td>
<td>Biological E, India</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>VACCINE TYPE</th>
<th>Typbar TCV®</th>
<th>TYPHIBEV®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vi polysaccharide from <em>Salmonella Typhi</em> conjugated to tetanus toxoid carrier protein</td>
<td>Vi polysaccharide from <em>Citrobacter freundii</em> conjugated to CRM197 carrier protein*</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FORMULATION</th>
<th>Liquid: ready to use</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ADMINISTRATION</th>
<th>Intramuscular injection</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>AGES</th>
<th>≥6 months to ≤65 years</th>
<th>≥6 months to ≤45 years</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>NUMBER OF DOSES REQUIRED</th>
<th>1</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>WHO-PREQUALIFIED PRESENTATION(S) AVAILABLE WITH GAVI SUPPORT</th>
<th>5-dose vial</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>COLD CHAIN VOLUME</th>
<th>5-dose vial: 2.9 cm³/dose</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>SHELF LIFE</th>
<th>36 months at storage temperature: 2-8°C</th>
<th>24 months at storage temperature: 2-8°C</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>VACCINE VIAL MONITOR (VVM) TYPE</th>
<th>Type 30</th>
</tr>
</thead>
</table>

| USE IN ROUTINE IMMUNIZATION PROGRAMS | India (Navi Mumbai only), Liberia, Pakistan, Samoa, Zimbabwe | Malawi, Nepal |

October 2023

*Note: The Vi polysaccharide of *Citrobacter freundii* is structurally and immunologically the same as the Vi polysaccharide in *Salmonella* Typhi. (Rondini S et al. Evaluation of the immunogenicity and biological activity of the *Citrobacter freundii* Vi-CRM197 conjugate as a vaccine for *Salmonella enterica* serovar Typhi. *Clinical Vaccine Immunology*. 2011;18(3):460-468.)

Learn more and join the effort at www.takeontyphoid.org · #TakeOnTyphoid